Cancer vaccine developer restructures after axing lead drug trial
Immune Design's stock price dropped more than 30 percent on the decision, which pushes the prospects of FDA approval several years into the future.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Casey Coombs Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Vaccines | Health Management | Vaccines